Streetbeat News

Price Targets

INTU

BMO Capital analyst Daniel Jester has maintained an Outperform rating on Intuit (NASDAQ:INTU) and increased the price target from $605 to $640, indicating a positive outlook on the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:52 pm

CRWD

BMO Capital analyst Keith Bachman has maintained an Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and increased the price target from $227 to $238.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:49 pm

CRWD

Wedbush analyst Taz Koujalgi has reiterated an Outperform rating on CrowdStrike Holdings (NASDAQ:CRWD) and maintained a $200 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:38 pm

NTAP

Wedbush analyst Matt Bryson has maintained a Neutral rating on NetApp (NASDAQ:NTAP) and increased the price target from $75 to $85.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:35 pm

AZO

Wedbush analyst Seth Basham has reiterated an Outperform rating on AutoZone (NYSE:AZO) and maintained a price target of $2750 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:32 pm

SKX

Wedbush analyst Tom Nikic has maintained an Outperform rating on Skechers USA (NYSE:SKX) and increased the price target from $59 to $62.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:29 pm

BLDR

Wedbush analyst Jay McCanless has reiterated an Outperform rating on Builders FirstSource (NYSE:BLDR) and maintained a price target of $175.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:27 pm

SHOO

Wedbush analyst Tom Nikic has reiterated a Neutral rating on Steven Madden (NASDAQ:SHOO) and maintained a price target of $36.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:25 pm

TOL

Wedbush analyst Jay McCanless has reiterated a Neutral rating on Toll Brothers (NYSE:TOL) and maintained the price target of $82.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:23 pm

ANAB

Wedbush analyst David Nierengarten has reiterated a Neutral rating on AnaptysBio (NASDAQ:ANAB) and maintained a $20 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 1:21 pm